Apr 22, 2026 08:30AM
Apr 22, 2026 08:30AM
Apr 7, 2026 08:50AM
May 22, 2025 04:05PM
May 22, 2025 04:01PM
Dec 4, 2024 08:06AM
Dec 4, 2024 08:05AM Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Jul 8, 2024 08:35AM
Jun 11, 2024 09:05AM
May 9, 2024 08:45AM
Apr 29, 2024 09:00AM
Mar 22, 2024 07:36AM
Mar 22, 2024 07:35AM
Mar 18, 2024 05:10PM Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Mar 12, 2024 08:05AM
Mar 12, 2024 08:05AM
Dec 22, 2023 08:05AM
Dec 19, 2023 08:05AM
Dec 19, 2023 08:05AM
Dec 6, 2023 08:05AM
Dec 6, 2023 08:05AM Outlook Therapeutics® Announces Strategic Organizational Realignment
Nov 1, 2023 08:05AM
Sep 21, 2023 08:05AM
Aug 1, 2023 08:45AM
May 15, 2023 08:05AM
Apr 27, 2023 08:05AM
Mar 13, 2023 07:00AM
Feb 14, 2023 08:05AM Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
Feb 7, 2023 08:05AM
Jan 19, 2023 08:05AM
Jan 9, 2023 08:05AM
Dec 29, 2022 09:07AM
Dec 29, 2022 09:05AM
Dec 23, 2022 09:00AM
Dec 23, 2022 06:01AM Outlook Therapeutics (OTLK) Prices 28.46M Share Direct Offering at $0.88/sh
Dec 23, 2022 06:00AM
Dec 22, 2022 08:06AM
Dec 22, 2022 08:05AM
Dec 1, 2022 08:05AM
Nov 22, 2022 08:05AM
Oct 28, 2022 08:06AM
Oct 28, 2022 08:05AM Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Sep 27, 2022 08:05AM
Sep 27, 2022 08:05AM
Sep 26, 2022 08:35AM
Sep 7, 2022 08:05AM
Aug 30, 2022 08:05AM
Aug 15, 2022 08:05AM
Aug 10, 2022 08:05AM Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
Aug 4, 2022 08:05AM

322,870 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All